Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly & Co. stock underperforms Thursday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,745.37 and the Dow Jones Industrial Average DJIA rising 0.62% to 42,175.11.
Is Eli Lilly Stock Still a Buy Near All-Time Highs?
Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in August. With the shares up nearly 68% in the past 52 weeks and 58.5% year-to-date,
1d
on MSN
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
BioSpace
1d
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...
1d
Novo faces ‘Nokia risk’ as it fights Lilly’s homecourt advantage
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
13h
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
3d
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Opinion
Culpepper Star Exponent
20h
Opinion
LILLY: Does America have the will to be healed?
Politics, though controversial, this year presents one single theme that I think we can all agree on. Our government needs a ...
9d
Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
BioSpace
4d
Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...
journalgazette
1d
Lead On: Lilly organization announces new leadership development academy
The Lilly Endowment Inc. keeps pouring into leaders, and Michelle Love thinks she has more she could pour out, too.
4d
on MSN
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
15h
on MSN
Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
Novo Nordisk
Japan
Donanemab
Food and Drug Administration
Feedback